Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

Graham, J., McBride, D., Stull, D. et al. (7 more authors) (2016) Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. Pharmacoeconomics, 34 (8). pp. 815-827. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2016 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Dates:
  • Published (online): 21 May 2016
  • Published: August 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 06 Jul 2016 12:01
Last Modified: 10 Oct 2016 14:13
Published Version: http://dx.doi.org/10.1007/s40273-016-0412-1
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-016-0412-1
Related URLs:

Share / Export

Statistics